In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Vascular: The Now-Ready-For-Prime-Time Player

Executive Summary

Four years ago, lured into a mainstream cardiovascular business by the promise of drug-eluting stents, Abbott set about revamping its medical products business in an effort to create a device business that would rival its pharmaceutical business in financial returns. What was at first a niche strategy, aimed at bringing small, but interesting technologies to interventionalists, has become a more broad-based play that, company officials hope, will place them among the leaders in vascular devices.

You may also be interested in...



Ireland's Medtech Explosion

Over the last three decades, Ireland has built a robust medical device community serving large multi-national device companies, built on favorable tax policies and a strong manufacturing and engineering base. But now Ireland is trying to incubate a robust start-up community as well, focused on R&D and innovation, hoping to create the next Medtroniic or Covidien rather than simply serving the current ones.

Ireland's Medtech Explosion

Over the last three decades, Ireland has built a robust medical device community serving large multi-national device companies, built on favorable tax policies and a strong manufacturing and engineering base. But now Ireland is trying to incubate a robust start-up community as well, focused on R&D and innovation, hoping to create the next Medtroniic or Covidien rather than simply serving the current ones.

Abbott Ventures: Building A Venture Portfolio in Devices

Corporate venture investing has become an increasingly important source of capital as traditional venture firms remained squeezed. In devices, the latest entrant into the field is Abbott Ventures, which sees itself as an extension of Abbott's internal efforts to build its device pipeline, favoring mid-stage deals in technology and therapeutic areas that fit strategically with Abbott's existing device businesses.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel